✓ Translated by DotMD AI Clinical Council Source: Metabolism: clinical and experimental • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #10690940 ↗

Randomized Controlled Trial: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin (N = 27)

Original Paper Title: “Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 27
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CETP activity was reduced by 10.3% and 26.4% with the low and high dose of atorvastatin. Together, these composition data would be consistent with a net reduction in the number of TG-rich lipoproteins that may be explained by (1) a reduction in VLDL synthesis, (2) a preferential removal of VLDL without conversion to LDL, and (3) a prefere.
  • Study Design & Sample: Randomized Controlled Trial published in Metabolism: clinical and experimental (N = 27 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Metabolism: clinical and experimental (2000), this randomized controlled trial evaluating 27 human participants investigated: Atorvastatin is a new hepatic hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor that has been demonstrated to be efficacious in reducing both triglyceride (TG) and cholesterol (CHOL) levels in humans. Key clinical takeaway: CETP activity was reduced by 10.3% and 26.4% with the low and high dose of atorvastatin. Together, these composition data would be consistent with a net reduction in the number of TG-rich lipoproteins that may be explained by (1) a reduction in VLDL synthesis, (2) a preferential removal of VLDL...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Metabolism: clinical and experimental, 2000-02-15; N = 27; Rigor 82/100): CETP activity was reduced by 10.3% and 26.4% with the low and high dose of atorvastatin. Together, these composition data would be consistent with a net reduction in the number of TG-rich lipoproteins that may be explained by (1) a reduction in VLDL synthesis, (2) a preferential removal of VLDL without conversion to LDL, and (3) a prefere.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: atorvastatin-calcium → Rx: atorvastatin-calcium-film-coated → Rx: pressure-pain-and-mucus-acetaminophen-guaifenesin-phenylephrine-hcl → Rx: sinus-pressure-plus-pain-pe-acetaminophen-and-phenylephrine → Condition: cholesterol → Condition: triglycerides →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 10690940: Randomized Controlled Trial: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin (N = 27)

3 of 3 Free Questions Remaining